Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.4 USD | +0.92% | -4.35% | -36.00% |
Apr. 16 | SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update | CI |
Apr. 02 | HC Wainwright Adjusts Price Target on SAB Biotherapeutics to $6 From $10, Maintains Buy Rating | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 40.22M |
---|---|---|---|---|---|
Net income 2024 * | -45M | Net income 2025 * | -57M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.02
x | P/E ratio 2025 * |
-0.71
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.39% |
1 day | +0.92% | ||
1 week | -4.35% | ||
Current month | -3.08% | ||
1 month | -9.84% | ||
3 months | -26.67% | ||
6 months | -55.09% | ||
Current year | -36.00% |
Managers | Title | Age | Since |
---|---|---|---|
Eddie Sullivan
FOU | Founder | 58 | 21-10-21 |
Samuel Reich
CEO | Chief Executive Officer | 49 | 21-10-21 |
Michael King
DFI | Director of Finance/CFO | 63 | 23-10-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 68 | 21-10-21 | |
Jeffrey Spragens
BRD | Director/Board Member | 82 | 21-10-21 |
Erick Lucera
BRD | Director/Board Member | 57 | 23-04-02 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 4.4 | +0.92% | 731 |
24-04-23 | 4.36 | -0.68% | 858 |
24-04-22 | 4.39 | +2.33% | 1,741 |
24-04-19 | 4.29 | -3.81% | 891 |
24-04-18 | 4.46 | -3.04% | 2,927 |
Delayed Quote Nasdaq, April 24, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.00% | 40.22M | |
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B |
- Stock Market
- Equities
- SABS Stock